Meta-analysis of primary care delivered buprenorphine treatment retention outcomes

References

• US. Department of Health and Human Services. 2023. Opioid facts and statistics. https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html.
   Google Scholar
• Substance Abuse and Mental Health Services Administration Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health. 2018. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on drug use and Health. https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report.
   Google Scholar
• Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (Update). The CBHSQ Report. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017 Aug 22.
   Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication assisted treatment. Am J Public Health. 2015;105:e55–e63. doi:10.2105/AJPH.2015.302664.
   PubMed Web of Science ®Google Scholar
• Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff (Millwood). 2020;39:984–92. doi:10.1377/hlthaff.2019.01622.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O’Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addiction. 2008;17:116–20. doi:10.1080/10550490701860971.
   PubMed Web of Science ®Google Scholar
• Gertner AK, Robertson AG, Powell BJ, Jones H, Silberman P, Domino ME. Primary care provider and specialists deliver comparable buprenorphine treatment quality. Health Aff (Millwood). 2020;39:1395–404. doi:10.1377/hlthaff.2019.01559.
   PubMed Web of Science ®Google Scholar
• Haddad MS, Zelenev A, Altice FL. Buprenorphine treatmentretention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2014;92:193–213. doi:10.1007/s11524-014-9924-1.
   Web of Science ®Google Scholar
• Korthuis PT, King C, Cook RR, Khuyen TT, Kunkel LE, Giang LM, Nguyen T, Thuy DT, Bielavitz S, Nguyen DB. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in vietnam (BRAVO): an open-label randomized, non-inferiority trial. Lancet HIV. 2021;8:e67–e76. doi:10.1016/S2352-3018(20)30302-7.
   PubMed Web of Science ®Google Scholar
• Cunningham CO. Opioids and hiv infection: from pain management to addiction treatment. Top Antivir Med. 2018;25:143–46.
   PubMedGoogle Scholar
• Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat. 2017;75:38–42. doi:10.1016/j.jsat.2017.01.015.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhu H, Ghitza UE. Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: results from electronic health records data. Drug Alcohol Depen. 2018;192:316–23. doi:10.1016/j.drugalcdep.2018.08.013.
   PubMed Web of Science ®Google Scholar
• Kunins HV, Sohler NL, Giovaniello A, Thompson D, Cunningham CO. A buprenoprphine education and training program for primary care residents: implementation and evaluation. Subst Abus. 2013;34:244–47. doi:10.1080/08897077.2012.752777.
   Web of Science ®Google Scholar
• Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: benefits and barriers. J Addict Med Ther Sci. 2015;1:31–36. doi:10.17352/2455-3484.000008.
   PubMedGoogle Scholar
• Hammick M, Dornan T, Steinert Y. Conducting a best evidence review. Part 1: from idea to data coding BEME Guide No.13. Med Teach. 2010;32:3–15. doi:10.3109/01421590903414245.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Matthews ML, Brick D, Nguyen MT, Jamison RN, Ellner AL, Tishler LW, Weiss RD. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and chronic pain patients using opioid non-medically. J Opioid Manag. 2014;10:159–68. doi:10.5055/jom.2014.0204.
   PubMedGoogle Scholar
• Stein MD, Cioe P, Friedmann PD. Brief report: buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038–41. doi:10.1111/j.1525-1497.2005.0228.x.
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37:426–30. doi:10.1016/j.jsat.2009.05.003.
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine. Arch Intern Med. 2011;171:425–31. doi:10.1001/archinternmed.2010.541.
   PubMed Web of Science ®Google Scholar
• Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70. doi:10.1016/j.jsat.2016.12.010.
   PubMed Web of Science ®Google Scholar
• Weinstein LC, Iqbal Q, Cunningham A, Debates R, Landistratis G, Doggett P, Silverio A. Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017-2018. Am J Public Health. 2020;110:580–86. doi:10.2105/AJPH.2019.305525.
   PubMed Web of Science ®Google Scholar
• Riggins DP, Cunningham CO, Ning Y, Fox AD. Recent incarceration and buprenorphine treatmentoutcomes among human immunodeficiency virus-positive patients. Subst Abus. 2016;38:297–302. doi:10.1080/08897077.2016.1220443.
   PubMed Web of Science ®Google Scholar
• Cunningham C, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, Sohler N. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;41:500–06.
   Google Scholar
• Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, Cunningham CO. Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010;38:153–59. doi:10.1016/j.jsat.2009.08.001.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav. 2010;35:537–40. doi:10.1016/j.addbeh.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2008;24:226–32. doi:10.1007/s11606-008-0866-8.
   PubMed Web of Science ®Google Scholar
• Hsu YJ, Marstellar JA, Kachur SG, Fingerhood MI. Integration of buprenorphine treatment with primary care: comparative effectiveness on retention, utilization, and cost. Popul Health Manag. 2019;22:292–99. doi:10.1089/pop.2018.0163.
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Moore BA, O’Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict. 2009;19:53–58. doi:10.1111/j.1521-0391.2009.00003.x.
   Web of Science ®Google Scholar
• Larochelle MR, Slavova S, Root ED, Feaster DJ, Ward PJ, Selk SC, Knott C, Villani J. Samet JH.Disparities in opioid overdose death trends by race/ethnicity, 2018-2019, from the HEALing communities study. Am J Public Health. 2021;111:851–1854. doi:10.2105/AJPH.2021.306431.
   Web of Science ®Google Scholar
• Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants -United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67:349–58. doi:10.15585/mmwr.mm6712a1.
   PubMed Web of Science ®Google Scholar
• O’Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants — 24 states and the district of columbia, January–June 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1189–97. doi:10.15585/mmwr.mm6935a1.
   PubMed Web of Science ®Google Scholar
• Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115:946–58. doi:10.1111/add.14878.
   PubMed Web of Science ®Google Scholar